Allarme dei pediatri, infezioni in crescita nell’autunno 2022 e anche a inizio 2023
Risultati per: Nuovo test rapido per distinguere le infezioni virali
Questo è quello che abbiamo trovato per te
The MaxCombo Test Severely Violates the Type I Error Rate—Reply
In Reply We would like to thank Magirr and Burman for their thoughtful comments on our systematic review and meta-analysis and will address some of their concerns.
The MaxCombo Test Severely Violates the Type I Error Rate
To the Editor In their recent systematic review and meta-analysis in JAMA Oncology, Mukhopadhyay et al compare 3 statistical tests based on historic immuno-oncology trials with registrational intent. Unsurprisingly, they conclude that the so-called MaxCombo test has higher power to demonstrate a treatment difference. However, they misleadingly cite one of our articles, claiming that this test controls the type I error. On the contrary, our publications demonstrate that MaxCombo is not valid to show benefit of a candidate drug. A better alternative to the standard log-rank test is the modestly weighted test.
THE PRECIOUS STUDY: A PROSPECTIVE, OBSERVATIONAL STUDY OF CD8+ BIOMARKER BASED PROGNOSTIC TEST IN NORTH AMERICAN IBD PATIENTS
The clinical course of IBD varies considerably among patients1. One barrier to personalized medicine in IBD is the lack of a reliable prognostic assay that can be used at diagnosis to guide effective therapy for each patient, to optimize clinical outcomes and minimize complications. To address this need, a whole-blood qPCR-based prognostic assay was developed to divide IBD patients into two subgroups2. This transcriptional signature yields CD8 T-cell exhaustion level data that correlated with disease outcomes among IBD patients in UK2.
Autismo, un test molecolare per diagnosticarlo
Centro ricerche Altamedica,individua mutazioni geniche collegate
FDA Approves First Over-the-counter Combined COVID-19 and Flu Test
In late February, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization to an at-home diagnostic test that identifies SARS-CoV-2, the virus that causes COVID-19, as well as influenza strains A and B. The test detected 100% of negative and 88.3% of positive COVID-19 samples, 99.3% of negative and 90% of positive influenza A samples, and 99.9% of negative influenza B samples.
Response by Tabák et al to Letters Regarding Article, “Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study”
Circulation, Volume 147, Issue 12, Page 988-989, March 21, 2023.
Letter by Deng et al Regarding Article, “Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study”
Circulation, Volume 147, Issue 12, Page 985-986, March 21, 2023.
Letter by Schmidt et al Regarding Article, “Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study”
Circulation, Volume 147, Issue 12, Page 987-987, March 21, 2023.
Randomized Trial of Facilitated Adherence to Screening-Colonoscopy Versus Sequential Fecal-Based Blood Test
Colorectal cancer (CRC) screening guidelines include screening-colonoscopy and sequential high sensitivity fecal occult blood testing (HSgFOBT), with expectation of similar effectiveness based on the assumption of similar high adherence. However, adherence to screening-colonoscopy compared to sequential HSgFOBT has not been reported. In this randomized clinical trial, we assessed adherence and pathology findings for a single screening-colonoscopy versus sequential and non-sequential HSgFOBT.
Usa, Fda autorizza primo test casalingo per Covid-influenza
E’ un tampone nasale, risultati in 30 minuti
What should the standard be for passing and mastery on the Critical Thinking about Health Test? A consensus study
Objective
Most health literacy measures rely on subjective self-assessment. The Critical Thinking about Health Test is an objective measure that includes two multiple-choice questions (MCQs) for each of the nine Informed Health Choices Key Concepts included in the educational resources for secondary schools. The objective of this study was to determine cut-off scores for passing (the border between having and not having a basic understanding and the ability to apply the nine concepts) and mastery (the border between having mastered and not having mastered them).
Design
Using a combination of two widely used methods: Angoff’s and Nedelsky’s, a panel judged the likelihood that an individual on the border of passing and another on the border of having mastered the concepts would answer each MCQ correctly. The cut-off scores were determined by summing up the probability of answering each MCQ correctly. Their independent assessments were summarised and discussed. A nominal group technique was used to reach a consensus.
Setting
The study was conducted in secondary schools in East Africa.
Participants
The panel included eight individuals with 5 or more years’ experience in the following areas: evaluation of critical thinking interventions, curriculum development, teaching of lower secondary school and evidence-informed decision-making.
Results
The panel agreed that for a passing score, students had to answer 9 of the 18 questions and for a mastery score, 14 out of 18 questions correctly.
Conclusion
There was wide variation in the judgements made by individual panel members for many of the questions, but they quickly reached a consensus on the cut-off scores after discussions.
Adenoma Detection Rate and Colorectal Cancer Risk in Fecal Immunochemical Test Screening Programs
Annals of Internal Medicine, Ahead of Print.
Truffa dei tamponi: dai clienti per i test malgrado positivo
(v. “Tamponi dell’Asl per amici e parenti…” delle 12.29)
Medici italiani in Turchia, 'Ora rischio di infezioni'
Servizi di base saltati. ‘Un collega salvato dopo 9 ore di lavoro’
Tumore colon-retto, aumentano casi ma 7 su 10 non fanno test
Oncologi Aiom, via campagna sensibilizzazione.Coinvolte farmacie